Chemical Compound Review:
Canertinib HCl N-[4-[(3-chloro-4-fluoro- phenyl)amino]-7...
Synonyms:
CHEMBL31965, S1019_Selleck, CHEMBL545315, cc-446, SureCN2052123, ...
This record was replaced with 156414.
- Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. Yang, H., Kim, S.K., Kim, M., Reche, P.A., Morehead, T.J., Damon, I.K., Welsh, R.M., Reinherz, E.L. J. Clin. Invest. (2005)
- Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. Campos, S., Hamid, O., Seiden, M.V., Oza, A., Plante, M., Potkul, R.K., Lenehan, P.F., Kaldjian, E.P., Varterasian, M.L., Jordan, C., Charbonneau, C., Hirte, H. J. Clin. Oncol. (2005)
- The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Erlichman, C., Boerner, S.A., Hallgren, C.G., Spieker, R., Wang, X.Y., James, C.D., Scheffer, G.L., Maliepaard, M., Ross, D.D., Bible, K.C., Kaufmann, S.H. Cancer Res. (2001)
- Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Simon, G.R., Garrett, C.R., Olson, S.C., Langevin, M., Eiseman, I.A., Mahany, J.J., Williams, C.C., Lush, R., Daud, A., Munster, P., Chiappori, A., Fishman, M., Bepler, G., Lenehan, P.F., Sullivan, D.M. Clin. Cancer Res. (2006)
- Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Rao, G.S., Murray, S., Ethier, S.P. Int. J. Radiat. Oncol. Biol. Phys. (2000)
- Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033. Dorow, D.S., Cullinane, C., Conus, N., Roselt, P., Binns, D., McCarthy, T.J., McArthur, G.A., Hicks, R.J. Eur. J. Nucl. Med. Mol. Imaging (2006)
- Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. Nelson, J.M., Fry, D.W. J. Biol. Chem. (2001)
- Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. Willmarth, N.E., Ethier, S.P. J. Biol. Chem. (2006)
- Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Nemunaitis, J., Eiseman, I., Cunningham, C., Senzer, N., Williams, A., Lenehan, P.F., Olson, S.C., Bycott, P., Schlicht, M., Zentgraff, R., Shin, D.M., Zinner, R.G. Clin. Cancer Res. (2005)
- Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Nyati, M.K., Maheshwari, D., Hanasoge, S., Sreekumar, A., Rynkiewicz, S.D., Chinnaiyan, A.M., Leopold, W.R., Ethier, S.P., Lawrence, T.S. Clin. Cancer Res. (2004)
- Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer. Tiseo, M., Loprevite, M., Ardizzoni, A. Current medicinal chemistry. Anti-cancer agents. (2004)
- Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor. Christensen, J.G., Vincent, P.W., Klohs, W.D., Fry, D.W., Leopold, W.R., Elliott, W.L. Mol. Cancer Ther. (2005)
- Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. Smaill, J.B., Showalter, H.D., Zhou, H., Bridges, A.J., McNamara, D.J., Fry, D.W., Nelson, J.M., Sherwood, V., Vincent, P.W., Roberts, B.J., Elliott, W.L., Denny, W.A. J. Med. Chem. (2001)
- CI-1033, a pan-erbB tyrosine kinase inhibitor. Slichenmyer, W.J., Elliott, W.L., Fry, D.W. Semin. Oncol. (2001)
- Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line. Skvortsov, S., Skvortsova, I., Sarg, B., Loeffler-Ragg, J., Lindner, H., Lukas, P., Tabernero, J., Zwierzina, H. Apoptosis (2005)